[ad_1]
Sydney, Feb. 11, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
- Chimeric Therapeutics Ltd (ASX:CHM) has retained a mid-case valuation of 74 cents per share from RaaS Advisory after revealing encouraging data from the second dose cohort of its CLTX CAR T Phase 1 dose-escalation study for patients with recurrent or progressive glioblastoma (GBM). Click here
- Radiopharm Theranostics Ltd (ASX:RAD) has attracted a $0.84 share price valuation in initial coverage from Diamond Equity Research. Click here
- Magnis Energy Technologies Ltd ((ASX:MNS, OTCQX:MNSEF) continues to advance its wholly-owned Nachu Graphite Project in Tanzania towards production. Click here
- Euro Manganese Inc ((ASX:EMN, TSXV:EMNOTCQX:EUMNF) has closed a C$8,499,500 strategic equity investment with the European Bank for Reconstruction and Development (EBRD). Click here
- SensOre Ltd has joined the local bourse under the ticker ‘S3N’. Click here
- Critical Resources Ltd (ASX:CRR) has received approval for 1,200 metres of additional drilling across …
Full story available on Benzinga.com
[ad_2]
Source link
